Fisetin.

Fisetin and quercetin are closely related flavonols with near-identical structures, so they scavenge overlapping reactive oxygen species and act through similar antioxidant chemistry. Formulators pair them because their flavonol activity runs in parallel rather than competing.

When fisetin neutralizes a free radical it is left in an oxidized form, and ascorbate donates electrons to return it to the active flavonoid. The two sustain each other inside the water-phase antioxidant network.

Flavonols like fisetin donate electrons to the spent tocopheroxyl radical, restoring vitamin E to its active form after it quenches a lipid radical in cell membranes. This recycling keeps membrane antioxidant defense turning over.

Fisetin is rapidly conjugated by glucuronidation and cleared from circulation, and piperine slows those same conjugating enzymes. This is the established reason the two are co-dosed, to keep more fisetin available for absorption.

Fisetin is itself oxidised as it quenches radicals, and cellular thiols can return oxidised flavonols to their reduced form. Glutathione is the main cytosolic thiol pool, so its status shapes how long a flavonol keeps cycling.

Lipoic acid regenerates the ascorbate and tocopherol pools, and ascorbate in turn returns oxidised flavonols to their reduced form. That places fisetin downstream of lipoic acid in the same antioxidant relay.

Both polyphenols are cleared largely by intestinal glucuronidation and both activate the Nrf2 antioxidant response element. Because they compete for the same conjugating capacity, circulating exposure to each can run higher when they are taken together.

Flavonols carry catechol and hydroxyl groups that bind ferric iron in the gut lumen and form complexes the intestine cannot take up. Taken in the same dose window, fisetin lowers absorption of non-heme iron, so the two are better separated by a couple of hours.

Catechins and flavonols are both handled by intestinal UGT and SULT enzymes with limited capacity. Given together each occupies conjugation sites the other would use, which can raise the unconjugated fraction of both.

The catechol group on fisetin's B-ring binds copper and iron, the same chemistry that gives catechol flavonols their metal-chelating character. In the gut lumen that binding lowers the free mineral available for uptake, and in solution a flavonol-copper complex can behave differently from either partner alone. Separating doses is the practical handling.

Flavonols form coordination complexes with divalent cations including zinc, which reduces the free ion available at the transporter in a co-ingested dose. The same complexation has been used deliberately as an ionophore mechanism in cell work, which is a different setting from an oral supplement. In a formula, the practical point is that a large polyphenol dose and a mineral dose in one capsule are not independent.

Fisetin is poorly water soluble, and complexing a flavonol with phosphatidylcholine to make a phytosome is the standard route to raising its dissolution and membrane transit. The approach is well characterised for other flavonols. It changes exposure, not the compound.

Lecithin supplies the phospholipid used to build liposomal and phospholipid-complex fisetin, and it is the common allergen-free substitute for soy lecithin in that role. Its function is delivery rather than activity. The relevant question for a buyer is whether the phospholipid is actually complexed with the flavonol or merely blended alongside it.

Dissolving or suspending fisetin in medium-chain triglycerides raises the fraction presented in solution rather than as dry crystals, which is the limiting step for a compound this insoluble. Softgel formats use the oil for exactly this reason. Fat also stimulates bile flow, which aids solubilisation generally.

N-acetylcysteine supplies cysteine, the rate-limiting substrate for glutathione synthesis, and fisetin is described as raising the expression of glutathione-linked enzymes through Nrf2 signalling. Raising the enzymes without the substrate leaves the pathway short. The pairing is substrate plus expression, which is the usual shape of an antioxidant combination.

Both are polyphenols studied for their effects on cellular ageing pathways, and both are extensively glucuronidated and sulphated on first pass. Co-dosing loads the same conjugating enzymes, which can raise the exposure of each above what it would be alone. That is a pharmacokinetic interaction rather than a demonstrated combined effect.

Pterostilbene is the dimethylated relative of resveratrol and is less rapidly conjugated, which is why it appears in cellular-ageing formulas alongside fisetin. The two act on overlapping described pathways from different chemical classes. No human combination data supports the pairing.

Luteolin is a catechol flavone handled by the same intestinal UGT and SULT enzymes that conjugate fisetin. Co-dosing means the two compete for a finite conjugation capacity, which raises free aglycone exposure for both. Whether that helps or simply shortens the window is not established.

Apigenin shares the flavone core and appears in the same senescence and cellular-ageing formulas as fisetin, and both are subject to heavy phase II conjugation. Apigenin also inhibits CD38, a route by which it is described as influencing NAD availability. The overlap is in formulation category and in conjugation, more than in a single shared target.

Rutin is quercetin bound to a disaccharide and must be hydrolysed by gut bacteria before its aglycone is absorbed, after which it enters the same conjugation pathway fisetin uses. In a stacked flavonoid formula the aglycones compete for UGT and SULT capacity. This is why single-flavonoid pharmacokinetics do not carry over to a blend.

NMN feeds the NAD salvage pathway while fisetin is studied for its action on senescent-cell survival signalling, two separate nodes in the same cellular-ageing literature. They are combined on that shared research theme rather than on a described chemical interaction. Read it as mechanistic rather than clinical.

Nicotinamide riboside is phosphorylated by nicotinamide riboside kinase to NMN and then to NAD, supplying the redox and signalling cofactor pool. Fisetin is not part of that pathway; it is combined with it because both are studied under the cellular-ageing heading. The precursor chemistry is established; the combination is convention.

Spermidine is described as inducing autophagy through hypusination of eIF5A and inhibition of acetyltransferase activity, a different lever from the senescent-cell survival pathways fisetin is studied on. Both come up in the same formulation category. Nothing describes a direct interaction between them.

Astaxanthin sits inside the membrane bilayer while a conjugated flavonol circulates in the aqueous compartment, so the two occupy different phases of the same antioxidant problem. Fisetin is described as acting on Nrf2-driven enzyme expression rather than by direct scavenging alone. The compartment split is the reason to combine them.

Ubiquinol is the lipid-phase antioxidant that regenerates alpha-tocopherol at the membrane and carries electrons in the respiratory chain. Fisetin's described activity sits in the signalling and water-phase compartment. Combining a membrane antioxidant with an Nrf2-directed polyphenol covers two different parts of the redox system.

Silymarin flavonolignans inhibit several UGT isoforms and hepatic transport, and fisetin's short plasma life is set by exactly that conjugation. Co-administration would be expected to raise fisetin exposure. That cuts both ways: the same inhibition applies to anything else in the formula that UGT handles.

Urolithin A is a gut bacterial metabolite of ellagitannins described as inducing mitophagy, while fisetin is studied on senescent-cell pathways. Both circulate mainly as glucuronides, so both are exposure-limited by the same conjugation step. They are combined on the shared cellular-ageing theme rather than on joint data.